HR 6509, the SAFE Drugs Act of 2025, limits how often pharmacies and healthcare providers can create custom drug formulations that copy standard medications. It restricts compounding any drug essentially identical to a commercially available product to no more than 20 times per month for individual patients. The bill also requires pharmacies compounding such drugs for out-of-state patients more than 20 times monthly to report details to the FDA, while exempting hospital pharmacies. These changes aim to improve safety oversight of non-standard drug compounding by setting clear limits and reporting rules.
SRES 533 is a non-binding Senate resolution condemning white supremacy, hate, and antisemitism, with specific focus on the promotion of these ideologies by white supremacist Nick Fuentes and his platforming by Tucker Carlson. It highlights Fuentes' Holocaust denial, antisemitic conspiracy theories (like the "Great Replacement" myth), and use of dog whistles, while criticizing Carlson for hosting Fuentes without challenge and Heritage Foundation's Kevin Roberts for defending such views. The resolution urges all elected officials and leaders to reject these ideologies whenever they occur, and affirms condemnation of Nazism and the Holocaust. As a formal expression of Senate opinion, it does not create new laws but serves as a public stance against harmful rhetoric.
HRES 933 is a non-binding House resolution expressing support for victim service providers who assist survivors of domestic violence, dating violence, sexual assault, and stalking. It acknowledges these providers - such as shelters, nonprofits, and community organizations - help survivors navigate legal, medical, and emotional challenges, including safety planning and connecting to resources. The resolution highlights their critical but often underfunded role and calls for meaningful investment to sustain their lifesaving work. (Note: As a resolution, it does not create new laws or funding but formally recognizes the need for support.)
Skinny Labels, Big Savings Act This bill provides a statutory safe harbor from patent infringement claims for generic or biosimilar manufacturers that seek or obtain approval for skinny labels of their drugs. Under current law, the Food and Drug Administration (FDA) may approve generic and biosimilar drugs through a process known as skinny labeling, which allows a generic manufacturer to seek approval only for approved uses of the drug that are no longer protected by patents. However, in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc. , a court held that a generic manufacturer may sometimes be liable for patent infringement when it markets skinny label generics. The bill specifically lists the following as actions that are not considered infringement of a method of use claim in a patent under the Federal Food, Drug, and Cosmetic Act: submitting or seeking approval of a skinny label for a generic or biosimilar drug; promoting or commercially marketing a drug with skinny labeling approved by the FDA; or describing a drug product approved by the FDA as a generic of, or therapeutically equivalent to, the branded drug. The bill also applies the safe harbor to similar actions under the Public Health Service Act.
This bill removes barriers for people with past drug-related convictions to access federal assistance programs. It amends welfare law to allow states to provide Temporary Assistance for Needy Families (TANF) benefits to individuals with such convictions and prohibits states from denying Supplemental Nutrition Assistance Program (SNAP) benefits based on drug convictions. The bill also adds "incarcerated individuals scheduled for release within 30 days" to SNAP household eligibility criteria. These changes directly affect individuals with past drug convictions seeking welfare or food assistance, removing state-level restrictions that previously barred them.
HRES 926, the RESPECT Resolution, is a non-binding House resolution urging states to adopt equity-focused cannabis policies. It recommends specific actions to address racial disparities, including eliminating criminal penalties for cannabis possession, creating fairer business licensing (prioritizing communities harmed by past enforcement), automatically expunging cannabis convictions, and reinvesting tax revenue in affected communities. The resolution also calls for the U.S. to advocate at the United Nations for cannabis descheduling from international drug treaties. It directly affects states, localities, and communities disproportionately impacted by cannabis prohibition, particularly communities of color.
HRES 932 is a symbolic resolution passed by the House of Representatives that condemns six specific members of Congress (including Senators Kelly and Slotkin and Representatives Crow, Deluzio, Goodlander, and Houlahan) for allegedly making statements that encouraged military and intelligence personnel to disobey orders from the President. The resolution claims these lawmakers falsely suggested the administration issued "illegal orders" and undermined the military chain of command, violating the Uniform Code of Military Justice (UCMJ). It does not create new laws or policies but formally denounces the lawmakers' statements as "dangerous and seditious rhetoric." As a procedural resolution, it has no binding effect on military conduct or policy.
This bill prohibits U.S. military action against Venezuela without specific new congressional authorization. It blocks funding for Defense Department operations involving "hostilities" (defined as any use of lethal force by U.S. forces) except under two conditions: a new law passed after this bill's enactment, or a congressional authorization meeting War Powers Resolution standards. Key exceptions allow self-defense, protection of U.S. personnel, lawful counternarcotics operations, and humanitarian aid. The bill does not override the War Powers Resolution but requires stricter authorization for military engagement with Venezuela.
HR 6475, the Preventing Child Trafficking Act of 2025, requires the Department of Justice's Office for Victims of Crime and the Administration for Children and Families' Office on Trafficking in Persons to implement the 2023 Government Accountability Office's recommendations for preventing child trafficking and supporting survivors. The bill mandates these agencies to collaborate using established best practices, develop measurable performance goals for child trafficking programs, and base these targets on existing grantee data. It directly affects federal agencies managing anti-trafficking programs and the children and survivors served by those programs. The bill requires a report to Congress within 180 days detailing how these implementation steps were carried out.
HR 6466, the Forced Abortion Prevention and Accountability Act, prohibits non-consensual administration of abortion drugs (like mifepristone or misoprostol) to pregnant women without their informed consent. It criminalizes this act with penalties up to 25 years in prison and allows victims to sue for triple damages, psychological/physical injury compensation, and attorney fees. The bill directly affects pregnant women who might face coerced procedures and medical providers or others who administer such drugs without consent. Key provisions include criminal penalties for the act itself, enhanced penalties for serious injury or death, and a civil remedy framework for victims seeking compensation.
The Freedom to Heal Act of 2025 creates a new federal registration process for physicians to directly administer Schedule I investigational drugs under the "Right to Try" framework. It requires physicians to apply to the Attorney General with evidence of state compliance, manufacturer agreements, and training, and limits the amount of drugs they may possess based on approved applications. The bill mandates the Attorney General to issue interim rules within 240 days and final rules within two years covering drug delivery, storage, recordkeeping, and registration management. This affects physicians treating eligible patients with Schedule I drugs under federal Right to Try provisions, not the patients themselves.
HR 6423, the HELP Copays Act, requires health insurance plans and coverage to count financial assistance from non-profits or drug manufacturers toward patient cost-sharing limits like deductibles and copayments. This directly affects patients enrolled in health insurance who receive such assistance for prescription drugs, ensuring the help they get reduces their out-of-pocket costs faster. The bill amends key health laws to mandate that these payments are included when calculating whether a patient has met their deductible or copayment threshold. The change applies to all prescription drugs, including specialty drugs and those subject to prior authorization, but does not alter how insurers manage drug access through tools like step therapy. It takes effect for plan years starting in 2026.
